Thailand and the compulsory licensing of efavirenz

Article Abstract:

Merck, which has a patent for efavirenz drug in Thailand, has objected to Thailand's unilateral action of issuing the compulsory license for the efavirenz drug and wants the Thais to consider other options of buying efavirenz at lower price or it might provide a voluntary license for the production of a generic version similar to South Africa. Thailand has placed an order for efavirenz with Ranbaxy, a large Indian pharmaceutical company as an interim measure while its Government Pharmaceutical Organization is testing the bioequivalence of the generic efavirenz that has already formulated.

Government regulation, Pharmaceutical preparations, Thailand, United States, Pharmaceutical industry, Licensing, certification and accreditation, Merck & Company Inc., Efavirenz (Medication)

---

Patients with multiple chronic conditions - how many medications are enough?

Article Abstract:

Researchers in Canada determined that elderly patients undergoing treatment for chronic diseases, such as diabetes and emphysema, are likely to be undertreated for other medical conditions. This may reflect a concern for prescribing multiple medications, with attendant side effects, insufficient time for office visits, or other factors. In the US, where prescription medications generally require some out-of-pocket expense to patients, this problem may be more severe. Research may determine which factors influence undertreatment, and how they might be corrected.

Health aspects, Aged, Elderly, Editorial, Drugs, Prescriptions (Drugs), Comorbidity

---

The controversy over Guidant's implantable defibrillators

Article Abstract:

Joshua Oukrop, a Minnesota teenager with hypertrophic cardiomyopathy and a high risk of sudden death from ventricular fibrillation, received an implantable cardioverter-defibrillator (ICD) on October 4, 2001. Oukrop on March 14, 2005 collapsed and died as the device had short-circuited internally, while trying to deliver high-voltage therapy.

United Kingdom, Care and treatment, Usage, Risk factors, Cardiomyopathy, Hypertrophic, Hypertrophic cardiomyopathy, Cardiac arrest, Implantable cardioverter-defibrillators

Similar abstracts:

• Abstracts: Lamivudine for patients with chronic hepatitis B and advanced liver disease. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
• Abstracts: Cancer Mortality Following Treatment for Adult Hyperthyroidism. Thyroid function and mortality in patients treated for hyperthyroidism
• Abstracts: Katrina survivors strive to reclaim their lives. A mental health intervention for schoolchildren exposed to violence: a randomized controlled trial
• Abstracts: Prevalence of child physical and sexual abuse in the community: results from the Ontario Health Supplement. Family violence research: Lessons learned and where from here?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.